Back to top

Analyst Blog

Merck KGaA (MKGAF) enrolled the first patient in a phase III study (ESPART) on Pergoveris. Merck KGaA is evaluating Pergoveris for multifollicular development as part of an Assisted Reproductive Technology (ART) treatment cycle in women classified as poor ovarian responders (POR).

The multicenter, randomized, controlled, single-blind, parallel Espart study is designed to assess the efficacy and safety of Pergoveris in comparison with Gonal-f (used in the treatment of infertility). The primary endpoint of the study is the total number of retrieved oocytes. Ongoing pregnancy rate, live birth rate, embryo implantation rate, clinical pregnancy rate and biochemical pregnancy rate constitute the secondary endpoints of the study.

As per the World Health Organization, over 72.4 million people are affected by infertility globally and 15% of them resort to medical treatments.

Infertility is one of the main focus area of Merck KGaA’s largest division, Merck Serono. This study is part of Merck KGaA’s commitment toward achieving the shared goal of increasing pregnancy rates and addressing the challenges to fertility.

Pergoveris is approved by the European commission/available in the EU for the stimulation of follicular development in women with severe luteinizing hormone (LH) and follicle stimulating hormone (FSH) deficiency.

Merck Serono’s revenues decreased 0.7% in 2013 due to currency headwinds of 4.6%. Rebif sales grew organically by 1.4% in the year. Gonal-f sales fell organically by 0.7% in 2013 due to an adverse foreign exchange impact of 3.5%.

Merck KGaA carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the MEDICAL sector may consider companies like Salix Pharmaceuticals Ltd. (SLXP - Analyst Report), Actavis (ACT - Analyst Report) and Lannett Co., Inc. (LCI - Snapshot Report). Actavis carries a Zacks Rank #2 (Buy) while Lannett and Salix carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%